Pozelimab (C5 Antibody) BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority ReviewGlobeNewsWire • 02/21/23
Regeneron Pharmaceuticals, Inc. (REGN) SVB Securities Global Biopharma Conference (Transcript)Seeking Alpha • 02/14/23
EYLEA® (aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) by the FDAGlobeNewsWire • 02/08/23
Drug, Chip Stocks Hit 52-Week Highs As One Breaks Out Of Bullish Chart PatternInvestors Business Daily • 02/03/23
Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock TopplesInvestors Business Daily • 02/03/23
Regeneron stock rallies after profit and revenue beat expectations by wide marginsMarket Watch • 02/03/23
Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating ResultsGlobeNewsWire • 02/03/23
Press Release: Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitisGlobeNewsWire • 01/30/23
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic EsophagitisGlobeNewsWire • 01/30/23
Regeneron, Sanofi's Dupixent is one step closer to approval for young children in EuropeMarket Watch • 01/27/23
Press Release: Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitisGlobeNewsWire • 01/27/23